US2015140130A1PendingUtilityA1
Treatment of neurological disorders
Assignee: VELACOR THERAPEUTICS PTY LTDPriority: Oct 3, 2007Filed: Jan 30, 2015Published: May 21, 2015
Est. expiryOct 3, 2027(~1.2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 3/08A61P 9/10A61P 25/04A61P 25/18A61P 25/24A61P 25/16A61P 27/16A61P 25/14A61P 25/28A61P 25/08A61P 25/00A61P 25/22A61K 31/46A61K 33/04A61K 31/15A61K 31/165A61K 31/4985A61K 45/06A61K 31/275A61K 31/48A61K 31/135A61K 31/137A61K 31/428A61K 31/12A61K 31/198A61K 31/473A61K 31/4453
28
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A treatment of a neurological disorder, including hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject involves administering an effective amount of selenate or a pharmaceutically acceptable salt thereof to the subject. The treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of the neurological disorder.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for the treatment of a neurological disorder selected from the group consisting of hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject comprising administering an effective amount of selenate or a pharmaceutically acceptable salt thereof, wherein the treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of said neurological disorder.
2 . The method according to claim 1 wherein the effective amount of selenate or a pharmaceutically acceptable salt thereof delivers a supranutritional amount of selenium.
3 . The method according to claim 2 wherein the supranutritional amount of selenium is 5 μg/kg to 1.0 mg/kg per day.
4 . The method according to claim 1 wherein the selenate is in the form of sodium selenate.
5 . The method according to claim 1 further comprising administration of the selenate or pharmaceutically acceptable salt thereof is in combination with another therapy for the treatment or prevention of neurological disorders selected from hypoxia, oxygen-glucose deprivation and acute brain trauma.
6 . A method according to claim 1 wherein the symptoms of stroke are caused by ischaemia.
7 . A method according to claim 6 wherein the acute brain trauma is traumatic brain injury.
8 . A method according to claim 2 wherein the supranutritional amount of selenium is 0.05 mg/kg to 1 mg/kg per day.Join the waitlist — get patent alerts
Track US2015140130A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.